News
Eli Lilly's experimental oral pill, orforglipron, shows promise in obesity treatment, with participants experiencing an ...
LLY's orforglipron study results disappoint, shifting investor focus to Novo Nordisk's bid for first FDA-approved oral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback